What is a Neurofibroma Neoplasm?
A neurofibroma is a benign peripheral nerve sheath tumor composed of Schwann cells, perineural cells, and endoneural fibroblasts that arises from peripheral nerves. 1
Basic Characteristics
Neurofibromas are benign tumors that can occur as:
- Isolated sporadic lesions in the general population
- Multiple tumors in patients with Neurofibromatosis Type 1 (NF1), where they represent the hallmark lesion 2
The tumor develops from cells that normally surround and support peripheral nerves, creating a proliferation of these supporting cells within the nerve structure.
Clinical Subtypes
Neurofibromas present in several distinct forms 3:
Cutaneous Neurofibromas (cNFs)
- Occur on or within the skin surface
- Begin appearing during puberty and increase with age 4
- Affect nearly 100% of NF1 patients eventually 5
- Very rarely, if ever, undergo malignant transformation 4
- Can cause cosmetic burden, tenderness, bleeding, itching, and significant negative effects on quality of life 4
Plexiform Neurofibromas
- Invasive variant involving nerves, muscle, tissues, and skeleton 6
- More destructive and can be disfiguring
- Carry risk of progression to malignant peripheral nerve sheath tumors (MPNST) 7
Localized/Diffuse Forms
- Present as discrete nodules or more widespread involvement
- Can occur in oral/maxillofacial regions (uncommon) 8
Molecular Basis
The development of neurofibromas, particularly in NF1, results from:
- Biallelic NF1 gene inactivation on chromosome 17q11.2 3, 2
- Loss of neurofibromin protein, which normally regulates the RAS proto-oncogene 2, 7
- This leads to uncontrolled cell growth and proliferation through RAS pathway activation 7
Progression Spectrum
Modern classification recognizes a progression spectrum 3:
- Benign neurofibroma (baseline)
- ANNUBP (Atypical Neurofibromatous Neoplasm of Uncertain Biologic Potential) - requires ≥2 of: cytologic atypia, loss of architecture, hypercellularity, or mitotic count >1/50 HPF but <3/10 HPF
- MPNST (Malignant Peripheral Nerve Sheath Tumor) - shows brisk mitotic activity and tissue necrosis
Critical caveat: The 2025 consensus now recommends renaming "low-grade MPNST" to "ANNUBP with increased proliferation" to avoid inappropriately labeling tumors of uncertain potential as malignant 3.
Clinical Presentation
Neurofibromas typically present as:
- Asymptomatic nodules or masses 8
- Painless swellings on skin or deeper tissues 6
- In NF1: multiple lesions with café-au-lait spots, Lisch nodules, and freckling 6
- Can occur anywhere but common sites include tongue, gingiva, orbital/periorbital regions 8, 6
Diagnostic Approach
For worrisome noncutaneous lesions in NF1 patients, molecular profiling is now recommended 3 to identify:
- CDKN2A/B inactivation (suggests ANNUBP)
- SUZ12, EED, or TP53 mutations (suggests MPNST)
- Significant aneuploidy (suggests MPNST)
This integrated histopathologic and genomic approach enables early identification of malignant transformation and appropriate intervention 3.
Treatment Implications
Benign neurofibromas are managed based on symptoms and location:
- Cutaneous lesions: surgical excision, CO2 laser ablation, or electrodesiccation 4
- Symptomatic plexiform neurofibromas require neurosurgical intervention 9
- No effective drug therapy currently exists for cutaneous forms 5
- Targeted therapies are under development based on RAS pathway understanding 2, 7
Key pitfall: While most neurofibromas remain benign, plexiform variants in NF1 patients require vigilant monitoring for malignant transformation, which carries poor survival rates 7.